The winners of BOB phase 1 and phase 2 of BOB 2010 are announced here. Learn more about the winners of past BOB events here.
Phase 2 - The winners!
In phase 2, the best business plans were selected. In total, 25 teams contested of which 11 belonged to Biotech, 11 to Medtech, 1 to Green Biotech, 1 to Bioinformatics and 1 to Supply and Services.
15 teams came from Austria, 4 from Germany, 2 from the USA, 1 from Hungary, 1 from Poland, 1 from India and 1 from Singapore. (60% Austria, 40% other countries). Of the 15 Austrian teams 9 came from Vienna, 1 from Lower Austria, 1 from Carinthia, 1 from Tyrol, 1 from Salzburg, 1 from Styria and 1 from Upper Austria (67% Vienna, 33% other federal states).
In August 2010, the 10 best teams were preselected. Of those teams, 6 belonged to Red Biotech, 4 to Medtech; 6 originated from Austria, 3 from Germany and 1 from Singapore.
The 10 best projects were invited to a coaching session on 15-16 September in Vienna, a two day intensive workshop. On October 20-21 an international jury selected the winners who were awarded the prizes on October 21 during the final award ceremony.
Please find the pictures of the winners and the award ceremony below.
Phase 1 - The three most innovative business ideas!
39 teams from 10 countries and 3 continents contested in phase 1 of the competition - a strong signal for the innovative and entrepreneurial power in the life sciences! 44% of the projects belonged to Medical Technology, 38% to Red Biotechnology and 15% to Supply and Services.
37 BOB evaluators from 7 countries performed a total of 234 evaluations providing detailed feedback to the participants.
On April 29th 2010, the three winning teams were presented to the public and awarded a cash prize of € 1,500 each at a ceremony held in the premises of Austria Wirtschaftsservice. Find below a short presentation of the winning teams in alphabetical order.
AMBERwest
Dr. Andreas KUBIN, Dr. Martina ZEDERBAUER
Development of selective inhibitors for human peroxidases for treatment of chronic inflammatory and neurodegenerative diseases.
Profem
Dr. Marion NOE
Development of a new combination therapy for the treatment of dermal and mucosal candidiasis, with special respect to vulvovaginitis caused by Candida spp., thereby introducing a therapeutic concept which takes host defense mechanisms into account. This project is complemented by an idea to develop compounds for the treatment of urge incontinence (UUI) and overactive bladder syndrome (OAB).
Sorbus
Dr. Frank SAMS-DODD
Discovery and development of novel treatments for complicated wounds, cancer and CNS disorders. The first product SertaSil has been shown to accelerate wound healing substantially and to treat wound infections in patients with acute and chronic wounds and burns.
Phase 1 Evaluators
37 BOB evaluators from 7 countries performed a total of 234 evaluations providing detailed feedback to the participants.
